Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ADARx Pharmaceuticals, Inc. (ADRX)

ADARx closes IPO at $17.00 per share, raising $446.3 million; AbbVie buys $89.3 million

Neutral Impact 4 of 5 financing Written later

ADARx Pharmaceuticals closed its initial public offering on September 28, 2026, selling 26,250,000 shares at $17.00 each for approximately $446.3 million in gross proceeds. AbbVie bought 5,255,542 shares in a concurrent private placement for approximately $89.3 million in gross proceeds, leaving it with about 4.9% of outstanding common stock after the closings. The company also adopted an amended and restated certificate of incorporation and bylaws in connection with the IPO.

Key points

  • IPO closed September 28, 2026: 26,250,000 shares at $17.00 per share, approximately $446.3 million in gross proceeds.
  • AbbVie bought 5,255,542 shares in a private placement at the IPO price, approximately $89.3 million in gross proceeds, owning about 4.9% after closing.
  • Placement agent fee was 2.0% of the private placement purchase price; J.P. Morgan, Morgan Stanley, TD Securities, UBS and LifeSci Capital acted as agents.
  • Amended and restated certificate of incorporation and bylaws took effect September 28, 2026.

The filing

CompanyADARx Pharmaceuticals, Inc. (ADRX)
Form8-K, current report
Filed with the SECSep 28, 2026, 4:01 PM ET
Accession number0001193125-26-405297

Items reported: 3.02 Unregistered Equity Sale5.03 Bylaw / Charter Amendment8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.